Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Lead Product(s): AIT-102
Therapeutic Area: Oncology Product Name: AIT-102
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AI Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 25, 2022